Analysts Trim Celldex Price Targets, Shares Fall
Celldex Therapeutics faces a flurry of analyst revisions, with Cantor Fitzgerald and Canaccord Genuity trimming targets to 61 and 60 while maintaining overweight/buy ratings, and Morgan Stanley lowering its target to 40, reflecting mixed sentiment. Meanwhile, firms like Guggenheim and Wells Fargo have raised targets to around 100 and 54 respectively, indicating a broad range of views on the stock’s near-term prospects as it trades in the mid-30s.
Finance · 7 sources · Jul 22, 2026Read itThe journal
Open the journal →The conversation starts in the journal — be the first to post.
About Canaccord Financial
Canaccord Genuity Group Inc. is an investment banking and financial services company that specializes in wealth management and brokerage in capital markets. It is one of the largest independent investment dealers in Canada. The firm focuses on growth companies, with operations in 10 countries. Canaccord Genuity, the international capital markets division, is based in Canada, with offices in the US, the UK, Europe, Asia, and Australia.
Everything about Canaccord Financial →- Headquarters
- Toronto
- Inception
- 1950